ITALIAN HEALTH COSTS, PRODUCTION NEWS

20 January 1992

The New Year has brought Italians a significant increase in the costs of their health care, following the turning of the 1992 finance bill into law by President Francesco Cossiga, who signed it after it had received parliamentary approval.

As a result of the new legislation the ticket, or patient contribution to the costs of medicines and other forms of treatment, has now been increased to 50% of the cost of the treatment or service, up from a level of 40% previously.

Moreover, the fixed ticket on prescriptions containing up to three drugs has now been set at a level of 3,000 lire ($2.61), while antibiotics and a few other specialties carry a 1,500-lire ticket. A ceiling of 70,000 lire ($60.88) has been established on tickets on tests and diagnostics, and the whole population, apart from those who are retired and living on a low income, are now required to pay these increases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight